| Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma RA Vaubel, S Tian, D Remonde, MA Schroeder, AC Mladek, GJ Kitange, ... Clinical Cancer Research 26 (5), 1094-1104, 2020 | 135 | 2020 |
| Automatic 3D Non-linear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data W Abdelmoula, M Regan, B Lopez, EC Randall, S Lawler, A Mladek, ... Analytical chemistry, 2019 | 55 | 2019 |
| Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma BM Marin, KA Porath, S Jain, M Kim, JE Conage-Pough, JH Oh, CL Miller, ... Neuro-oncology, 2021 | 40 | 2021 |
| Prefrontal θ-Burst Stimulation Disrupts the Organizing Influence of Active Short-Term Retrieval on Episodic Memory BM Marin, SA VanHaerents, JL Voss, DJ Bridge eNeuro 5 (1), 2018 | 11 | 2018 |
| Quantifying glioblastoma drug response dynamics incorporating treatment sensitivity and blood brain barrier penetrance from experimental data SC Massey, JC Urcuyo, BM Marin, JN Sarkaria, KR Swanson Frontiers in physiology 11, 830, 2020 | 9 | 2020 |
| Multimodal platform for assessing drug distribution and response in clinical trials B GC Lopez, IN Kohale, Z Du, I Korsunsky, WM Abdelmoula, Y Dai, ... Neuro-Oncology, 2021 | 4 | 2021 |
| THE ANTIBODY-DRUG CONJUGATE ABT-414 DEMONSTRATES SINGLE-AGENT ANTI-CANCER ACTIVITY ACROSS A PANEL OF GBM PATIENT-DERIVED XENOGRAFTS B Marin, A Mladek, D Burgenske, L He, Z Hu, K Bakken, B Carlson, ... NEURO-ONCOLOGY 20, 69-69, 2018 | 3 | 2018 |
| Quantifying glioblastoma drug response dynamics incorporating resistance and blood brain barrier penetrance from experimental data SC Massey, JC Urcuyo, BM Marin, JN Sarkaria, KR Swanson bioRxiv, 822585, 2019 | 2 | 2019 |
| Multimodal platform for assessing drug distribution and response in clinical trials. IN Kohale, Z Du, I Korsunsky, WM Abdelmoula, Y Dai, SA Stopka, ... Neuro-oncology, 2021 | | 2021 |
| DRES-12. QUANTIFYING INDIVIDUALIZED ABT-414 SENSITIVITY AND BLOOD-BRAIN BARRIER PENETRANCE FROM SERIAL IMAGING OF PATIENT-DERIVED XENOGRAFTS MODELS OF GLIOBLASTOMA J Urcuyo, SC Massey, BM Marin, J Sarkaria, K Swanson Neuro-Oncology 21 (Suppl 6), vi73, 2019 | | 2019 |
| Quantifying glioblastoma drug penetrance from experimental data SC Massey, J Urcuyo, BM Marin, J Sarkaria, KR Swanson bioRxiv, 650184, 2019 | | 2019 |
| IMAGING BASED INVASION METRIC PREDICTIVE OF RESPONSE TO ABT414 IN ORTHOTOPIC EGFRviii AMPLIFIED PATIENT DERIVED XENOGRAFTS SC Massey, B Marin, A Hawkins-Daarud, L Paulson, L Kasle, P Jackson, ... NEURO-ONCOLOGY 20, 270-271, 2018 | | 2018 |
| THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN G Muller-Greven, BM Marin, C Carlin, E Reilly, J Lee, M Bredel, J Sarkaria, ... NEURO-ONCOLOGY 20, 283-284, 2018 | | 2018 |
| Synthetic luciferin, CycLuc1, improves bioluminescence imaging for intracranial glioblastoma xenografts SK Gupta, M Kim, BM Marin, L He, K Swanson, T Tuma, BL Carlson, ... Cancer Research 78 (13 Supplement), 4112-4112, 2018 | | 2018 |
| Abstract W P47: Developing an Acute Lesion Atlas from Patients with Middle Cerebral Artery Stroke A Annasamudram, D Esterquest, BM Marin, M McSweeney, K Brandstatt, ... Stroke 46 (suppl_1), AWP47-AWP47, 2015 | | 2015 |
Susan Christine Massey, Ph. D.Associate Director, AI & Computational Biomedicine, Systems Oncology LLCVerified email at systemsoncology.com
